{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T15:48:24Z","timestamp":1782229704760,"version":"3.54.5"},"reference-count":42,"publisher":"American Diabetes Association","issue":"3","license":[{"start":{"date-parts":[[2026,6,7]],"date-time":"2026-06-07T00:00:00Z","timestamp":1780790400000},"content-version":"vor","delay-in-days":37,"URL":"https:\/\/www.diabetesjournals.org\/journals\/pages\/license"}],"funder":[{"DOI":"10.13039\/100000041","name":"American Diabetes Association","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000041","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,5,1]]},"abstract":"<jats:sec>\n                    <jats:title>OBJECTIVE<\/jats:title>\n                    <jats:p>To quantify the preventable disease burden and foregone economic benefits resulting from maintaining current limited access to obesity treatment among U.S. adults.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESEARCH DESIGN AND METHODS<\/jats:title>\n                    <jats:p>Using microsimulation modeling, we projected 10-year health and economic outcomes under three scenarios: current limited treatment access, expanded access to intensive lifestyle management or earlier-generation medications, and expanded access to glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide\u00a0(GIP)\/GLP-1 receptor agonists. The model simulated individual-level trajectories for 107.6 million adults with obesity across commercial insurance, Medicare, Medicaid, and uninsured populations, incorporating clinical outcomes, medical expenditures, productivity losses, quality-adjusted life-years, and mortality.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>By forgoing treatment, an estimated 5.3 million preventable deaths, 5.0 million diabetes cases, 5.5 million heart failure cases, 2.8 million strokes, 1.3 million myocardial infarctions, and 1.5 million obesity-related cancers would occur over 10 years. The economic cost of inaction totals $10.5\u2013$13.3 trillion in foregone benefits, including $1.8 trillion in avoidable medical expenditures, $3.0 trillion in lost productivity, and $5.6\u2013$8.5 trillion in diminished quality of life. Over the 10-year period, expanded access to intensive lifestyle management or earlier-generation medications would prevent 3% of deaths and 17\u201323% of major complications, while expanded access to incretin-based therapies would prevent 9% of deaths and 22\u201331% of complications.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONS<\/jats:title>\n                    <jats:p>Maintaining current limited treatment access results in substantial preventable disease burden and significant foregone economic benefits. Conventional framing focuses on intervention costs while ignoring ongoing expenses of untreated disease. This reframes the cost question from whether we can afford treatment to whether we can afford the consequences of inadequate access and intervention.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title\/>\n                  <\/jats:sec>","DOI":"10.2337\/doci25-0011","type":"journal-article","created":{"date-parts":[[2026,6,7]],"date-time":"2026-06-07T13:01:32Z","timestamp":1780837292000},"page":"306-319","update-policy":"https:\/\/doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":0,"title":["The Cost of Inaction in Treating Obesity in the U.S."],"prefix":"10.2337","volume":"1","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2198-1165","authenticated-orcid":false,"given":"Tanvi","family":"Sapra","sequence":"first","affiliation":[{"name":"GlobalData Plc 1 , New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Chen","sequence":"additional","affiliation":[{"name":"GlobalData Plc 1 , New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5106-9401","authenticated-orcid":false,"given":"Timothy M.","family":"Dall","sequence":"additional","affiliation":[{"name":"GlobalData Plc 1 , New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samar","family":"Hafida","sequence":"additional","affiliation":[{"name":"American Diabetes Association 2 , Arlington, VA"},{"name":"Boston University School of Medicine 3 , Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Moody","sequence":"additional","affiliation":[{"name":"GlobalData Plc 1 , New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Ferguson","sequence":"additional","affiliation":[{"name":"American Diabetes Association 2 , Arlington, VA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-1765-2391","authenticated-orcid":false,"given":"Tia","family":"Livingston","sequence":"additional","affiliation":[{"name":"GlobalData Plc 1 , New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuha A.","family":"ElSayed","sequence":"additional","affiliation":[{"name":"American Diabetes Association 2 , Arlington, VA"},{"name":"Harvard Medical School 4 , Boston, MA"},{"name":"Diabetes Education For All Foundation 6 , New York, NY"},{"name":"Supercharged Scientific 7 , Wellesley, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raveendhara R.","family":"Bannuru","sequence":"additional","affiliation":[{"name":"American Diabetes Association 2 , Arlington, VA"},{"name":"Harvard Medical School 4 , Boston, MA"},{"name":"Tufts University School of Medicine 5 , Boston, MA"},{"name":"Diabetes Education For All Foundation 6 , New York, NY"},{"name":"Supercharged Scientific 7 , Wellesley, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1167","published-online":{"date-parts":[[2026,6,7]]},"reference":[{"key":"2026062311014269800_B1","doi-asserted-by":"crossref","DOI":"10.15620\/cdc\/159281","article-title":"Obesity and Severe Obesity Prevalence in Adults: United States, August 2021\u2013August 2023","author":"Emmerich","year":"2024"},{"key":"2026062311014269800_B2","doi-asserted-by":"crossref","first-page":"101337","DOI":"10.1016\/j.ajpc.2025.101337","article-title":"Obesity-attributable risk of cardiovascular disease (CVD) in the United States: a Bayesian network analysis","volume":"24","author":"Sheth","year":"2025","journal-title":"Am J Prev Cardiol"},{"key":"2026062311014269800_B3","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/s41387-024-00352-9","article-title":"Assessing the economic impact of obesity and overweight on employers: identifying opportunities to improve work force health and well-being","volume":"14","author":"Dall","year":"2024","journal-title":"Nutr Diabetes"},{"key":"2026062311014269800_B4","doi-asserted-by":"crossref","first-page":"e0247307","DOI":"10.1371\/journal.pone.0247307","article-title":"Association of body mass index with health care expenditures in the United States by age and sex","volume":"16","author":"Ward","year":"2021","journal-title":"PLoS One"},{"key":"2026062311014269800_B5","doi-asserted-by":"crossref","first-page":"101429","DOI":"10.1016\/j.eclinm.2022.101429","article-title":"Excess mortality associated with elevated body weight in the USA by state and demographic subgroup: a modelling study","volume":"48","author":"Ward","year":"2022","journal-title":"EClinicalMedicine"},{"key":"2026062311014269800_B6","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1002\/oby.20662","article-title":"Eight-year weight losses with an intensive lifestyle intervention: the Look AHEAD Study","volume":"22","author":"Look AHEAD Research Group","year":"2014","journal-title":"Obesity (Silver Spring)"},{"key":"2026062311014269800_B7","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1001\/jama.2023.24945","article-title":"Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial","volume":"331","author":"Aronne","year":"2024","journal-title":"JAMA"},{"key":"2026062311014269800_B8","first-page":"3365","article-title":"Cost-effectiveness analysis of once-weekly semaglutide vs. once-daily liraglutide administered subcutaneously in patients with overweight and obesity: a decision analysis","volume":"28","author":"Alshahawey","year":"2024","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"2026062311014269800_B9","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1007\/s11695-017-3100-0","article-title":"Cost-effectiveness analysis of bariatric surgery for morbid obesity","volume":"28","author":"Alsumali","year":"2018","journal-title":"Obes Surg"},{"key":"2026062311014269800_B10","unstructured":"The White House\n          . Fact Sheet: President Donald J. Trump Announces Major Developments in Bringing Most-Favored-Nation Pricing to American Patients, 2025. Accessed 11 November 2025. Available from https:\/\/www.whitehouse.gov\/fact-sheets\/2025\/11\/fact-sheet-president-donald-j-trump-announces-major-developments-in-bringing-most-favored-nation-pricing-to-american-patients"},{"key":"2026062311014269800_B11","unstructured":"Williams\n              E\n            , RudowitzR, BellC. Medicaid Coverage of and Spending on GLP-1s. Kaiser Family Foundation, 2024. Accessed 8 May 2025. Available from https:\/\/www.kff.org\/medicaid\/issue-brief\/medicaid-coverage-of-and-spending-on-glp-1s\/"},{"key":"2026062311014269800_B12","unstructured":"Centers for Disease Control and Prevention\n          . Adult BMI Categories. 19 March 2024. Accessed 11 November 2025. Available from https:\/\/www.cdc.gov\/bmi\/adult-calculator\/bmi-categories.html"},{"key":"2026062311014269800_B13","doi-asserted-by":"crossref","first-page":"330","DOI":"10.2337\/doci25-0004","article-title":"Estimating the health, economic, and social benefits of obesity treatment using microsimulation modeling","volume":"1","author":"Chen","year":"2026","journal-title":"Diabetes, Obesity, and CardioMetabolic CARE"},{"key":"2026062311014269800_B14","doi-asserted-by":"crossref","first-page":"SP430","DOI":"10.37765\/ajmc.2024.89549","article-title":"Modeling the economic value of cardiometabolic virtual-first care programs","volume":"30","author":"Noble","year":"2024","journal-title":"Am J Manag Care"},{"key":"2026062311014269800_B15","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1177\/26350106221100779","article-title":"Impact of a digitally enhanced diabetes self-management program on glycemia and medical costs","volume":"48","author":"Chen","year":"2022","journal-title":"Sci Diabetes Self Manag Care"},{"key":"2026062311014269800_B16","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.amepre.2014.10.003","article-title":"Value of lifestyle intervention to prevent diabetes and sequelae","volume":"48","author":"Dall","year":"2015","journal-title":"Am J Prev Med"},{"key":"2026062311014269800_B17","doi-asserted-by":"crossref","first-page":"E61","DOI":"10.5888\/pcd20.230005","article-title":"State-specific prevalence of severe obesity among adults in the US using bias correction of self-reported body mass index","volume":"20","author":"Zhao","year":"2023","journal-title":"Prev Chronic Dis"},{"key":"2026062311014269800_B18","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1001\/jama.2023.2307","article-title":"Cardiovascular risk factor prevalence, treatment, and control in US adults aged 20 to 44 years, 2009 to March 2020","volume":"329","author":"Aggarwal","year":"2023","journal-title":"JAMA"},{"key":"2026062311014269800_B19","doi-asserted-by":"crossref","first-page":"e14656","DOI":"10.1111\/dme.14656","article-title":"Estimating risk factor progression equations for the UKPDS Outcomes Model 2 (UKPDS 90)","volume":"38","author":"Leal","year":"2021","journal-title":"Diabet Med"},{"key":"2026062311014269800_B20","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1161\/STROKEAHA.117.018928","article-title":"Revised Framingham Stroke Risk Score, nontraditional risk markers, and incident stroke in a multiethnic cohort","volume":"49","author":"Flueckiger","year":"2018","journal-title":"Stroke"},{"key":"2026062311014269800_B21","first-page":"1566","article-title":"Long-term effects of a lifestyle intervention on weight and cardiovascular risk factors in individuals with type 2 diabetes mellitus: four-year results of the Look AHEAD Trial","volume":"170","author":"Wing","year":"2010","journal-title":"Arch Intern Med"},{"key":"2026062311014269800_B22","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.amjcard.2023.07.118","article-title":"Age-related differences in the contribution of systolic blood pressure and biomarkers to cardiovascular disease risk prediction: the Atherosclerosis Risk in Communities (ARIC) Study","volume":"204","author":"Al Rifai","year":"2023","journal-title":"Am J Cardiol"},{"key":"2026062311014269800_B23","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1037\/amp0000517","article-title":"Lifestyle modification approaches for the treatment of obesity in adults","volume":"75","author":"Wadden","year":"2020","journal-title":"Am Psychol"},{"key":"2026062311014269800_B24","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1007\/s13679-020-00422-w","article-title":"Long-term efficacy and safety of anti-obesity treatment: where do we stand?","volume":"10","author":"Tak","year":"2021","journal-title":"Curr Obes Rep"},{"key":"2026062311014269800_B25","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/S0140-6736(10)60888-4","article-title":"Effect of Naltrexone Plus Bupropion on Weight Loss in Overweight and Obese Adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"376","author":"Greenway","year":"2010","journal-title":"Lancet"},{"key":"2026062311014269800_B26","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S0140-6736(97)11509-4","article-title":"Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group","volume":"352","author":"Sj\u00f6str\u00f6m","year":"1998","journal-title":"Lancet"},{"key":"2026062311014269800_B27","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/S0140-6736(11)60205-5","article-title":"Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial","volume":"377","author":"Gadde","year":"2011","journal-title":"Lancet"},{"key":"2026062311014269800_B28","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/oby.2011.330","article-title":"Controlled-release phentermine\/topiramate in severely obese adults: a randomized controlled trial (EQUIP)","volume":"20","author":"Allison","year":"2012","journal-title":"Obesity (Silver Spring)"},{"key":"2026062311014269800_B29","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1001\/jama.2021.23619","article-title":"Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes","volume":"327","author":"Rubino","year":"2022","journal-title":"JAMA"},{"key":"2026062311014269800_B30","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff","year":"2022","journal-title":"N Engl J Med"},{"key":"2026062311014269800_B31","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/S0140-6736(21)01443-4","article-title":"Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial","volume":"398","author":"Ludvik","year":"2021","journal-title":"Lancet"},{"key":"2026062311014269800_B32","unstructured":"Congressional Budget Office\n          . Long-term economic projections. Washington, DC, Congressional Budget Office; 2025. Accessed 3 March 2026. Available from https:\/\/www.cbo.gov\/data\/budget-economic-data#11"},{"key":"2026062311014269800_B33","doi-asserted-by":"crossref","first-page":"2250","DOI":"10.2337\/dc11-2478","article-title":"Health utility scores for people with type 2 diabetes in U.S. managed care health plans: results from Translating Research Into Action for Diabetes (TRIAD)","volume":"35","author":"Zhang","year":"2012","journal-title":"Diabetes Care"},{"key":"2026062311014269800_B34","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1177\/0272989X06290495","article-title":"Preference-Based EQ-5D index scores for chronic conditions in the United States","volume":"26","author":"Sullivan","year":"2006","journal-title":"Med Decis Making"},{"key":"2026062311014269800_B35","unstructured":"Institute for Clinical and Economic Review\n          . 2020-2023 Value Assessment Framework. Updated 23 October2020. Accessed 25 June 2025. Available from https:\/\/icer.org\/wp-content\/uploads\/2020\/10\/ICER_2020_2023_VAF_102220.pdf"},{"key":"2026062311014269800_B36","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1016\/S0140-6736(09)61457-4","article-title":"10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study","volume":"374","author":"Knowler","year":"2009","journal-title":"Lancet"},{"key":"2026062311014269800_B37","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1056\/NEJM200105033441801","article-title":"Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance","volume":"344","author":"Tuomilehto","year":"2001","journal-title":"N Engl J Med"},{"key":"2026062311014269800_B38","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1056\/NEJMoa2306963","article-title":"Semaglutide in patients with heart failure with preserved ejection fraction and obesity","volume":"389","author":"Kosiborod","year":"2023","journal-title":"N Engl J Med"},{"key":"2026062311014269800_B39","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes","volume":"389","author":"Lincoff","year":"2023","journal-title":"N Engl J Med"},{"key":"2026062311014269800_B40","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"2026062311014269800_B41","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"2026062311014269800_B42","unstructured":"GlobalData\n          . Economic Benefits of Obesity Treatment: Review of the Current Literature. 2025. Accessed 3 March 2026. Available from https:\/\/static1.squarespace.com\/static\/63ffa4761ca9af63a6201c5c\/t\/699f64e26ade317e86f2a9c7\/1772053731007\/EconomicBenefitsofObesityTreatmentLiteratureReview.pdf"}],"container-title":["Diabetes Obesity and Cardiometabolic CARE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/diabetesjournals.org\/docm-care\/article-pdf\/1\/3\/306\/881936\/docmi250011.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/docm-care\/article-pdf\/1\/3\/306\/881936\/docmi250011.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T15:22:40Z","timestamp":1782228160000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/docm-care\/article\/1\/3\/306\/170057\/The-Cost-of-Inaction-in-Treating-Obesity-in-the-U"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,1]]},"references-count":42,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,6,7]]},"published-print":{"date-parts":[[2026,5,1]]}},"URL":"https:\/\/doi.org\/10.2337\/doci25-0011","relation":{},"ISSN":["3067-3518","3067-3534"],"issn-type":[{"value":"3067-3518","type":"print"},{"value":"3067-3534","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,1]]}}}